International Journal of Alzheimer’s Disease

Microglia in Alzheimer’s Disease


Publishing date
01 Jun 2012
Status
Published
Submission deadline
01 Dec 2011

Lead Editor

1Department of Pathology and Laboratory Medicine, University of California Davis Medical Center, Sacramento, CA 95817, USA

2Department of Pharmacology, Physiology & Therapeutics, University of North Dakota School of Medicine and Health Sciences, Grand Forks, ND 58203, USA

3Harvard Medical School, Neuroimmunology & Innate Immunity Lab., Center for Immunology & Inflammatory Diseases and Division of Infectious Diseases, Massachusetts General Hospital, Charlestown, MA 02129, USA

4Department of Neuroimmunology, Research Institute of Environmental Medicine, Nagoya University, Fucho-cho, Chikusa, Nagoya 464-8601, Japan


Microglia in Alzheimer’s Disease

Description

Alzheimer's disease (AD) is the major cause of dementia and one of the most disabling health conditions worldwide. Microglia, the major inflammatory cells in the brain, play a pivotal role in the initiation and progression of AD. Despite current advances in our understanding of AD, the role of microglia in AD remains mysterious—microglia are either neuroprotective or neurotoxic. It is likely that the role of microglia in AD is not simplistically good or bad; they respond to stimuli with an array of activation profiles that depend on the age of the individual, the kind of stimuli, and modulation by neurons and astrocytes. New insights into the complex actions of microglia in AD will aid the development of therapeutic approaches that “fine-tune” the microglial activation profile to our advantage.

We invite investigators to contribute original research articles as well as review articles that will stimulate the continuing efforts to understand the actions of microglia in AD. Technically, microglia are hard to study because they are small, less abundant, and less immunoreactive than other neural cells in vivo and invariably become activated and altered when processed ex vivo. Therefore, we are also interested in articles describing novel methods to explore microglia. Potential topics include, but are not limited to:

  • Recent developments in microglial research techniques
  • Microglial stimuli in AD
  • Heterogeneity of microglial activation in AD
  • Regulation of microglial chemotaxis and phagocytosis
  • Role of microglial senescence/dystrophy in AD
  • Mechanism of neurotoxicity by microglia (including mechanisms related to Aβ and tau)
  • Therapeutic strategy targeting microglia (including clinical trials and epidemiological studies on anti-inflammatory reagents)

Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/ijad/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/ according to the following timetable:

International Journal of Alzheimer’s Disease
 Journal metrics
See full report
Acceptance rate11%
Submission to final decision95 days
Acceptance to publication26 days
CiteScore8.800
Journal Citation Indicator-
Impact Factor-
 Submit Check your manuscript for errors before submitting

We have begun to integrate the 200+ Hindawi journals into Wiley’s journal portfolio. You can find out more about how this benefits our journal communities on our FAQ.